Drug Profile
HTI 1066
Alternative Names: HTI-1066; SHR A1403Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater, Metastatic disease) in China (IV, Infusion)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV, Infusion)
- 13 Feb 2019 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in China (IV) (NCT03856541)